Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Use of Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis

Next Previous
X
Search
Trial Profile

Use of Voriconazole Inhalation Powder for the Treatment of Pulmonary Aspergillosis

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 25 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Voriconazole (Primary)
  • Indications Invasive bronchopulmonary aspergillosis
  • Focus Expanded access; Proof of concept; Therapeutic Use
  • Sponsors TFF Pharmaceuticals

    • Most Recent Events

    • 21 Nov 2024 Status changed from recruiting to completed.
    • 20 Mar 2024 According to a TFF Pharmaceuticals media release, on Wednesday, March 27, 2024 at 4:30 pm ET the Company will discuss data from the ongoing EAP for the treatment of invasive pulmonary aspergillosis (IPA).
    • 31 Jul 2023 According to a TFF Pharmaceuticals media release, the Uniphar Durbin Ireland Limited has been appointed to implement this expanded access Program in the United States, Australia, United Kingdom, Canada, and within select countries in Europe.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top